Ferrari, F.
Fierabracci, P.
Salvetti, G.
Jaccheri, R.
Vitti, J.
Scartabelli, G.
Meola, A.
Magno, S.
Ceccarini, G. http://orcid.org/0000-0003-0701-642X
Santini, F. http://orcid.org/0000-0002-1706-0822
Funding for this research was provided by:
Italian Ministry of the University (2017L8Z2EM)
Article History
Received: 19 May 2020
Accepted: 11 June 2020
First Online: 27 June 2020
Compliance with ethical standards
:
: F.F. has received travel funds from the following companies involved with lipodystrophy, obesity and/or diabetes treatments<b>:</b> Novo Nordisk, Aegerion, Amryt Pharmaceuticals.P.F has received travel funds from the following companies involved with obesity and/or diabetes treatments: Novo Nordisk, Bruno Farmaceutici, LJ Pharma. G.S. has received fees for sponsor seminar and travel funds from the following companies involved with obesity and/or diabetes treatments<b>:</b> Novo Nordisk, Penta. R.J. has received travel funds from the following companies involved with obesity and/or diabetes treatments<b>:</b> Novo Nordisk, Bioitalia, Nestlè, Kalibra. J.V. has received travel funds from the following companies involved with obesity and/or diabetes treatments<b>:</b> Novo Nordisk, Kalibra, GlaxoSmithKline. G.S. has received travel funds from the following company involved with obesity and/or diabetes treatments<b>:</b> Novo Nordisk. A.M. has received travel funds from the following company involved with obesity and/or diabetes treatments: Novo Nordisk. S.M. has received travel funds from the following companies involved with lipodystrophy, obesity and/or diabetes treatments<b>:</b> Novo Nordisk, Aegerion, Amryt Pharmaceuticals.G.C. has received fees for consulting, and/or received travel funds from the following companies that are involved with lipodystrophy, obesity and/or diabetes treatments: AstraZeneca, Aegerion, Novonordisk, Amryt Pharmaceuticals and Rhythm Pharmaceuticals. F.S. has worked as a consultant, participated in studies and/or received travel funds from the following companies that are involved with lipodystrophy, obesity and/or diabetes treatments: AstraZeneca, Aegerion, Amryt Pharmaceuticals, Bruno Farmaceutici, Novo Nordisk.
: All procedures performed in this study were in accordance with the ethical standards of the Local Ethical Committee and with the 1964 Helsinki declaration and its later amendments.
: Patients gave a general consent to the use of anonimysed data for research purpose.